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Developmental biology, as all experimental science, is empowered by technological advances. The availability of
genetic tools in some species - designated as model organisms - has driven their use as major platforms for understanding
development, physiology and behavior. Extending these tools to a wider range of species determines whether (and how)
we can experimentally approach developmental diversity and evolution. During the last two decades, comparative
developmental biology (evo-devo) was marked by the introduction of gene knockdown and deep sequencing
technologies that are applicable to a wide range of species. These approaches allowed us to test the developmental
role of specific genes in diverse species, to study biological processes that are not accessible in established models and,
in some cases, to conduct genome-wide screens that overcome the limitations of the candidate gene approach. The
recent discovery of CRISPR/Cas as a means of precise alterations into the genome promises to revolutionize
developmental genetics. In this review we describe the development of gene editing tools, from zinc-finger nucleases
to TALENs and CRISPR, and examine their application in gene targeting, their limitations and the opportunities they
present for evo-devo. We outline their use in gene knock-out and knock-in approaches, and in manipulating gene
functions by directing molecular effectors to specific sites in the genome. The ease-of-use and efficiency of
CRISPR in diverse species provide an opportunity to close the technology gap that exists between established
model organisms and emerging genetically-tractable species.
Keywords: Comparative developmental biology, Model organisms, Gene targeting, Homologous recombination,
Gene-editing nucleases, CRISPRReview
Evo-devo: driven by technological advances
Our understanding of developmental mechanisms is shaped
by the experimental models and approaches at hand.
The powerful genetic approaches available in Drosophila,
C. elegans, zebrafish, mice and Arabidopsis have largely
driven developmental research during the past decades,
focusing it on questions that are experimentally tractable
in these species. However, biological diversity greatly sur-
passes what can be studied in these organisms. Phenom-
ena such as regeneration, polyphenism and chromatin
diminution challenge some of our conventional views of
development, but are still poorly understood because they
are not accessible in our current experimental models.
Also, understanding the evolutionary paths by which di-* Correspondence: michalis.averof@ens-lyon.fr
1Institut de Génomique Fonctionnelle de Lyon (IGFL), École Normale
Supérieure de Lyon, 46 Allée d’Italie, Lyon 69364, France
Full list of author information is available at the end of the article
© 2014 Gilles and Averof; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.versity is generated requires that we compare develop-
mental mechanisms among several animals, well beyond
the established model organisms. Exploring these topics
requires extending our genetic approaches to new species.
Establishing genetic tools in new organisms has always
been a challenge for comparative developmental biology.
Evo-devo started to flourish when cloning genes and
studying their expression patterns in embryos could be
extended to a wide range of animals, with the advent of
PCR and whole-mount in situ hybridization techniques
in the 1990s. These techniques allowed ‘candidate genes’
to be associated with specific developmental events in
different animals and for evolutionary-developmental
hypotheses to be formulated based on this information.
Testing these hypotheses experimentally and exploring
alternative possibilities in an unbiased fashion became,
at that point, major challenges for the future of evo-
devo.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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were made since the late 1990s: the establishment of
gene knockdown approaches based on RNAi and other
antisense methods (see below) and the invention of
low-cost deep sequencing technologies, which opened
the door to unbiased genome-wide studies. Both methods
could be applied to a wide range of species. We will focus
here on functional genetics approaches.
The first important advance in this direction was made
with the discovery of RNA interference (RNAi), a mech-
anism that uses small RNAs (processed from larger
double-stranded precursors) to recognize and degrade
specific RNA targets [1-4]. RNAi is a natural mechanism
that evolved in eukaryotes to protect the genome against
invading viruses and transposons [4]. This defense
mechanism can be redirected to target specific mRNAs
of interest by providing double-stranded RNA match-
ing the target sequence. Since the RNAi machinery is
found naturally in most eukaryotes, RNAi-mediated
gene knockdown has turned out to be widely applic-
able. This approach has also been complemented by
other antisense methods that target RNA using different
types of oligonucleotides (morpholinos, antagomirs, LNAs
and others [5-8]). Together, these antisense approaches
have given us the opportunity to knock down gene
functions at the RNA level in a wide range of animals,
including cnidarians, arthropods, nematodes, planar-
ians, annelids, echinoderms, tunicates and vertebrates
(for example, [1,3,9-13]). RNAi-based screens in new
experimental models have allowed us to study biological
problems that were genetically intractable in the past,
such as tissue homeostasis and regeneration in planarians
[14] or particular aspects of insect physiology and devel-
opment in beetles (http://ibeetle.uni-goettingen.de/).
The flurry of RNAi and other antisense studies carried
out at the turn of the century revealed the power of these
approaches, but also their limitations. Besides technical
limitations relating to delivery, toxicity and off-target ef-
fects, for which solutions and appropriate controls can
often be found [15-17], there are intrinsic limitations in
the type of genetic manipulation that can be carried out:
interference with gene function is usually transient,
unlocalized, and primarily targets mRNA. Antisense
approaches do not usually allow us to achieve complete
loss of gene function, to perform stable genetic modifi-
cation, to pursue gain-of-function and conditional ap-
proaches, or to study cis-regulatory elements.
In some organisms, these knockdown approaches have
been complemented by transgenesis [18-24], which gives
access to stable genetic modification and gain-of-function
experiments via gene mis-expression. Transgenesis also
enables the use of reporter constructs to study cis-regula-
tory elements and to generate tools for live imaging, as
well as opportunities to generate mosaic animals, whereclones of cells can be marked, genetically modified and
compared to wild-type cells in the same individual [25].
The power of the transgenic approach in new experimen-
tal models can be seen, for example, in cell labeling and
tracing experiments carried out to study regenerative
progenitor cells in crustaceans and axolotls [26,27].
The development of transgenesis requires a significant
investment of time and effort, so this approach is still
limited to few species.
Among the functional approaches that are applicable
to a wide range of species, we can also count pharma-
cological treatments, which rely on the use of small
molecule effectors to interfere with specific regulatory
pathways [28].
Together, these technological advances allowed evo-
devo to advance from descriptive cross-species compari-
sons (in the 1990s) to comparisons of gene function
within a decade. In spite of this progress, most systems
are still lagging far behind standard models in terms of
experimental power and precision. The arrival of efficient
and widely applicable gene editing approaches is set to
narrow that gap, revolutionizing genetic approaches both
in established models and in emerging experimental
species.
Gene targeting approaches
The ability to modify a chosen sequence in its native
locus offers great advantages over conventional trans-
genesis and RNAi-mediated knockdown, both in terms
of versatility and precision. It enables us to manipulate
both coding sequences and cis-regulatory elements, to
perform gain- and loss-of-function experiments, and to
generate reporters and sensors that accurately reflect
endogenous gene expression and function. Manipulating
a gene in its native context is also a more precise ap-
proach because it allows us to study gene variants within
their native cis-regulatory environment, where they are
expressed in biologically meaningful levels and patterns.
Conventional gene targeting has exploited the natural
ability of cells to recombine DNA fragments that bear
homologous sequences, copying genetic changes from an
engineered template sequence to a homologous site in the
genome. In practice this often involves integrating an ex-
ogenous sequence, including appropriate markers, into the
locus of interest. The efficiency of this process is low, in the
order of 1 in 103-107 cells receiving the template DNA, and
it occurs among a high background of non-homologous in-
tegration events [29,30]. For this reason, conventional gene
targeting is workable only in systems where we are able to
screen very large numbers of transfected cells and select
the rare targeting events, for example, in cultured mamma-
lian cells and in yeast [29,31-33].
The efficiency of gene targeting, however, is strongly
enhanced (100 to 10,000-fold) when the targeted locus is
Figure 1 Gene targeting strategies using targeted double-strand
breaks. When chromosomal DNA is cleaved (red arrowhead), the
resulting double-strand break is repaired by non-homologous end
joining (NHEJ) or by homology-dependent repair (HDR). NHEJ
may result in perfect rejoining, of the ends, or in the introduction
of point mutations and indels (knock-out). NHEJ may also join exogenous
linear DNA (shown in yellow) to the broken ends of the chromosome
(homology-independent knock-in); the orientation and reading frame in
these insertions is random, unless directed by complementary overhangs
[42,44,45]. HDR repairs the double-strand break by precise copying of a
repair template carrying an exogenous sequence (shown in yellow)
flanked by sequences with homology to the targeted locus (in blue)
(homology-dependent knock-in). The repair template usually consists
of circular plasmid DNA with long homology arms [46-50] or short
single-stranded oligonucleotides (ssODNs) bearing 10 to 40 nucleotides
of homologous sequence at each end [48,50-52].
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example, double-strand breaks produced by the excision
of transposable elements are known to induce homolo-
gous recombination around the site of excision [39,40].
Thus, to improve the efficiency and specificity of gene
targeting, much attention has focused on directing
double-strand breaks to unique DNA sequences in the
genome.
Double-strand breaks can elicit two types of molecular
repair mechanism at the site of damage: non-homologous
end joining (NHEJ) in which the broken ends are re-
ligated to each other, or homology-directed repair (HDR)
in which the break is repaired using a homologous DNA
sequence as template (see [41]). NHEJ and HDR have
different consequences, which are both relevant for gene
editing. NHEJ is the predominant repair mechanism, but
it is error-prone, resulting in the introduction of small in-
sertions or deletions (indels) at the site of the break. Thus,
NHEJ provides an efficient way to disrupt gene function
(knock-out). In contrast, HDR is based on precise copying
of the template and can serve to insert specific changes
that have been engineered in the repair template (hom-
ology-dependent knock-in). NHEJ can also be used to
ligate the broken ends to an exogenous linear DNA
fragment, in the absence of sequence homology (hom-
ology-independent knock-in) [42-45]. NHEJ and HDR
are almost ubiquitous in living organisms, so these tar-
geting approaches (summarized in Figure 1) could in
principle be applied in any species of interest.
One of the first approaches for generating double-
strand breaks at specific sites in the genome exploited
natural sequence-specific endonucleases with long rec-
ognition sequences. These so-called ‘meganucleases’
recognize sequences that are typically 15 to 30 nucleo-
tides long, providing sufficient specificity to target unique
sequences in eukaryotic genomes. Meganucleases have
been successfully used in gene targeting [35,36], but
engineering these proteins to target new sequences has
proven to be a major challenge [53]. Another approach
has relied on artificial triple-helix-forming oligonucleo-
tides [54,55], but the scope of this approach is also limited
because triple-helix formation is only possible with some
sequences. Endonucleases with customizable sequence
specificities have been a dream of gene targeting since the
1990s.
Modular gene editing nucleases: zinc-finger nucleases
and TALENs
A major breakthrough came with the realization that
modular DNA recognition domains could be exploited
combinatorially to generate nucleases targeting a wide
range of sequences [56]. The zinc-finger domain, which
typically recognizes 3-nucleotide motifs on DNA, was
the first to be exploited in this way. Artificial enzymes,called zinc-finger nucleases (ZFNs), were engineered by
joining several zinc-finger domains - recognizing adja-
cent trinucleotide motifs - to the catalytic domain of the
endonuclease FokI (reviewed in [57]). Sequence-specificity
was further increased by engineering ZFNs in a way that
requires their heterodimerization through the FokI
domain for efficient cleavage [58]. Thus, targeting an
18-nucleotide target site could (in principle) be achieved
by a ZFN pair carrying 6 zinc-finger domains with the
appropriate sequence specificities. To date, ZFNs have
been used to target many genes in diverse organisms,
exploiting both NHEJ-mediated knock-out and HDR-
mediated knock-in approaches [57].
Despite their success in demonstrating the power of
the modular approach, ZFNs suffer two major draw-
backs that have limited their use. First, not all sequences
can be targeted by ZFNs, because zinc-finger modules
are not yet available for all possible nucleotide triplets
(for example, [59]). Second, the sequence specificity of
individual zinc-finger domains cannot always be pre-
cisely defined, and may be influenced by neighboring do-
mains in the protein [60,61]. This context dependence
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to failures in targeting [62] and the need for costly
design and testing.
The modular approach was taken a step further with
the discovery of the TAL effector (TALE) DNA-binding
modules of Xanthomonas bacteria, and their simple
DNA recognition code [63,64]. TAL proteins are tran-
scription factors with a modular DNA-binding region
that consists of multiple tandem repeats. Each of these
repeats is a small DNA binding domain capable of
recognizing a single nucleotide; two amino acid residues
within each repeat determine its specificity for A, G, C
or T, and this specificity is not significantly influenced
by neighboring domains [65]. Thus, using the same
combinatorial logic that was applied to ZFNs, TAL ef-
fector nuclease (TALEN) heterodimers with pre-defined
sequence specificities can be generated by assembling
multiple TAL repeats - one per nucleotide of the target
site - linked to the catalytic domain of FokI [66-68].
Thus, a 24-nucleotide sequence can be targeted by
generating a TALEN heterodimer, where each monomer
consists of an array of 12 TAL repeats fused to FokI.
TALENs offer three great advantages over ZFNs. First,
the modularity of the TAL domains and the simplicity of
their DNA recognition code mean that virtually any
sequence can be targeted by TALENs. Second, the
specificity of TAL domains does not appear to be as
context-dependent as that of zinc fingers, which re-
sults in more accurate predictions of target specificity
and a higher targeting success rate. Third, gene targeting
experiments in diverse species reveal that TALENs are
very efficient, yielding targeting efficiencies as high as 30
to 100% for NHEJ-mediated knock-outs and 1 to 10% for
HDR-mediated knock-ins (measured as the fraction of
injected individuals giving rise to progeny carrying a
targeted allele). High targeting rates have been achieved in
a wide range of organisms, including insects, nematodes,
annelids, tunicates, vertebrates and diverse plants [69-76].
The fact that each TAL domain targets a single nucleo-
tide means that long TAL arrays need to be assembled
in order to target unique sequences in a eukaryotic gen-
ome. Ingenious protocols have been developed for this
purpose [77-79], bringing TALEN technology within the
reach of every competent molecular biology lab.
Simple and efficient gene editing using the RNA-guided
nuclease CRISPR/Cas9
The last two years have seen the development of a new
approach to build endonucleases with customized sequence
specificities, which has revolutionized gene editing by its
simplicity and efficiency. The approach is borrowed from a
highly efficient immune mechanism of bacteria and archaea,
which employs RNA-guided endonucleases to specifically
target and degrade viral DNA [80-82] (reviewed in [83]).The genomes of many prokaryotes possess hypervari-
able loci, termed clustered regularly interspaced short
palindromic repeats (CRISPR), which incorporate short
sequences from invading viruses and express them in
the form of CRISPR-derived RNAs (crRNAs). These
small RNAs associate with specific CRISPR-associated
(Cas) proteins to form an active CRISPR/Cas endonucle-
ase complex, whose specificity is determined by simple
base complementarity between crRNA and the target
viral DNA. Immunity to a viral infection is determined
by the presence of corresponding viral sequences in
CRISPR loci [80,84,85]. The CRISPR mechanism bears
some striking analogies with eukaryotic RNAi and piRNA-
mediated defense mechanismsa [83,86].
In a ground-breaking study published in 2012, Jinek and
colleagues demonstrated that this nucleotide-based recogni-
tion mechanism could provide a straightforward approach
for generating customizable nucleases for gene targeting
[87]. They used the CRISPR system of Streptococcus
pyogenes, which involves a single Cas protein (Cas9)
and two RNAs (crRNA and trans-acting antisense
RNA, also known as tracRNA) to build an active
CRISPR/Cas endonuclease complex. Jinek et al. showed
that it is possible to combine these two RNAs into a single
chimeric guide RNA (known as gRNA or sgRNA) that can
efficiently direct Cas9 activity to specific DNA targets
in vitro (Figure 2). The guide RNA has a region of 20
nucleotides at its 5′ end, which binds the target DNA and
determines specificity; any 20-nucleotide sequence (N20)
can be placed at that siteb. The 3′ region of the guide
RNA, corresponding to the bacterial tracRNA, is an in-
variable sequence that is required to form a complex with
Cas9.
Target recognition also depends on additional interac-
tions between Cas9 and the target DNA, which require
the presence of a specific sequence motif, the ‘protospa-
cer adjacent motif ’ (PAM), immediately downstream of
the 20-nucleotide sequence targeted by the guide RNA.
The PAM sequence does not have a counterpart on the
guide RNA (Figure 2). Streptococcus pyogenes CRISPR/
Cas9 requires a PAM that is NGG; it can thus target any
sequence that matches the motif N20NGG. Once a target
is bound, two separate nuclease domains of Cas9 are in-
volved in cleaving each strand of the target DNA. Cleav-
age occurs within the guide RNA target region, usually
three nucleotides upstream of the PAM [81,82,87].
Within less than two years since the first demonstra-
tion of CRISPR-mediated gene editing [89-93], there has
been an explosion of reports describing the application
of CRISPR in diverse animal and plant species (reviewed
in [94]). The approaches to generate knock-outs and
knock-ins are similar to those previously described for
ZFNs and TALENs, relying on the endonuclease to gen-
erate a double-strand break at the targeted locus and on
Figure 2 CRISPR/Cas9 interacting with target DNA. The CRISPR/Cas9
complex of Streptococcus pyogenes consists of the Cas9 protein (in gray)
and a guide RNA that is a chimera of natural crRNA and tracRNA (in
orange). The targeting sequence at the 5′end of the guide RNA
base-pairs with complementary sequences on the target DNA (in
blue); the targeting sequence is 20 nucleotides long, but may be
shortened to increase specificity [88] (the addition of 1 to 2 unpaired
nucleotides at the 5′ end is also tolerated [51,88]). The presence of a
PAM (protospacer adjacent motif, NGG for Streptococcus pyogenes),
located immediately downstream of the 20-nucleotide sequence
targeted by the guide RNA, is also essential for target recognition
and cleavage. The PAM sequence does not have a counterpart on
the guide RNA. Following recognition of the PAM and base-pairing
between the guide RNA and the target, Cas9 cleaves each of the target
DNA strands a few nucleotides upstream of the PAM (red arrowheads).
Each strand is cleaved by a different nuclease domain present in Cas9
(HNH and RuvC domains). These domains have been mutated
independently to generate Cas9 nickases [82,87].
Gilles and Averof EvoDevo 2014, 5:43 Page 5 of 13
http://www.evodevojournal.com/content/5/1/43the cell’s imprecise or template-directed mechanisms of
repairing that break (Figure 1). However, compared to
ZFNs and TALENs, CRISPR has radically improved the
accessibility of gene targeting due to its straightforward
approach for customizing sequence specificity, via target-
specific guide RNAs. Its targeting efficiencies are compar-
able with the best efficiencies achieved using TALENs
in a wide range of animals and plants (for example,Table 1 Comparison of ZFN, TALEN and CRISPR approaches
ZFN




Difficult (commercial services expensive)




Target range Limited by range and context-dependence
of ZF modules




High throughput targeting No
asee [71,103]. PAM, protospacer adjacent motif; TALEN, TAL effector nuclease; ZFN,[46,51,95,96]), including organisms where gene target-
ing is not yet widely available, such as silkmoths, axo-
lotls, Xenopus and monkeys [97-100]. Moreover, while
TALEN activity is inhibited by DNA methylation [101],
CRISPR activity does not appear to be so [102]. Table 1
summarizes the relative benefits and drawbacks of
ZFNs, TALENs and CRISPR.
CRISPR delivery and target range
Different approaches have been used to deliver gene-
editing nucleases into target cells, including microinjec-
tion and transfection. CRISPR systems require the delivery
of Cas9 together with guide RNA. Cas9 may be expressed
from a helper plasmid carrying the coding sequence of
Cas9 (fused with a nuclear localization signal and
sometimes ‘codon-optimized’) under the control of an
appropriate promoter. Alternatively, if a promoter is
unavailable, Cas9 can be provided in the form of
in vitro transcribed capped mRNA or as purified re-
combinant protein [104,105]. In established models,
such as Drosophila, transgenic strains have been gener-
ated that express Cas9 in the germ line [47,48,96].
Delivery of the guide RNA is more constrained be-
cause in vitro transcription or plasmid-derived expres-
sion impose some limitations on the sequence of the
RNA and may, therefore, influence the range of potential
targets. In vitro transcription of RNA is usually carried
out using the RNA polymerase of bacteriophages T7, T3
or SP6, which generate transcripts that start with GG
(T3 or T7 RNA polymerase) or GA (SP6 polymerase)
[106]. The alternative to in vitro synthesis is to express
the guide RNA from a plasmid or transgene in vivo.
Small RNAs are conventionally expressed using RNA
polymerase III promoters, because they often require
precisely defined initiation and termination sites and
should not enter the mRNA processing pathway. Thus,
guide RNAs are usually expressed via the U6 snRNATALEN CRISPR
DNA break targeted by
protein-DNA recognition
DNA break targeted by RNA-DNA
base complementarity
Feasible in most labs but
labor intensive
Easy (see Table 2)
High High
High with most nucleases High with most guide RNAs
Unlimited Limited by PAM sequence
(potentially unlimited)
Yes Yes
Sensitive to CpG methylation Not sensitive to CpG methylation
Limited Yes
zinc-finger nuclease.
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scripts that start with a G.
In principle, these sequence constraints dictate that,
using Streptococcus pyogenes Cas9 (with NGG as a
PAM), we can optimally target sequences that contain
GGN18NGG or GAN18NGG motifs using in vitro tran-
scribed guide RNAs and GN19NGG using the U6 pro-
moter to drive guide RNA expression. In practice,
however, it seems that mismatches at the 5′ end of the
guide RNA are well tolerated, giving acceptable levels of
gene targeting [51,88]. Moreover, alternative guide RNA
expression strategies are emerging, which overcome the
constraints imposed by the U6 promoter [108-110].
Thus, the PAM sequence may be the only stringent limi-
tation to CRISPR’s target range.
PAM recognition seems to play a key role in CRISPR
target recognition [111], so the requirement for a PAM
in the target sequence is likely to remain. The se-
quence constraints imposed by the PAM may be over-
come by exploiting the natural diversity of CRISPR
systems [112-114], or by rational design and artificial
selection of Cas9 variants that recognize different
PAM sequences.
Off-target effects
Whether using ZFNs, TALENs or CRISPR, targeting a
chosen, unique sequence in the genome may be accom-
panied by unintended cleavage at other loci. Several
studies have investigated the specificity and potential
off-targets of CRISPR [89,102,115-121], focusing on the
stringency of base-pairing between the guide RNA and
the target. These studies have established that mis-
matches are tolerated, especially at the 5′ end of the
guide RNA, but that there are no simple rules predicting
the likelihood of mis-targeting based on the number and
position of mismatches. In some cases, even sequences
with multiple mismatches to the guide RNA were tar-
geted efficiently [116]. In one study, targeting specificity
deteriorated when high concentrations of CRISPR/Cas9
were used [118].
A recent study has also highlighted the role played by
the PAM sequence as CRISPR/Cas9 interrogates com-
plex DNA sequences to identify target sites [111]. The
study shows that the CRISPR/Cas9 complex first identi-
fies potential targets based on the PAM sequence, and
then interrogates these for sequence complementarity
with the guide RNA. The complex does not appear to
interact with sequences that match the guide RNA
targeting motif (N20) but have no adjacent PAM. These
observations suggest that off-targets will generally not
include sequences that are lacking the PAM. In species
where the genome sequence is known, computational
tools are now routinely used to select guide RNAs and
to evaluate potential off-targeting based on sequencesimilarity and on the presence of a PAM (see Online
Resources for CRISPR in Table 2).
A number of approaches can be taken to confront the
off-target problem and to mitigate its effects. First, it is
often possible to control for unspecific effects through
appropriate experimental design. A strategy commonly
employed in RNAi studies is to examine whether con-
sistent phenotypes are obtained by targeting different
parts of a gene, using non-overlapping double-stranded
RNA fragments or siRNAs [17]. The same strategy can
be easily applied in most cases of gene targeting by
CRISPR, by using different guide RNAs. Guide RNAs
targeting different sequences are very unlikely to share
the same off-target effects. Notably, heteroallelic combi-
nations of knock-outs generated using different guide
RNAs are likely to complement off-target mutations and
to give highly specific knock-out phenotypes.
Strategies for improving the specificity of CRISPR are
also beginning to emerge, exploiting the combined ac-
tion of pairs of CRISPR nucleases, or methods that in-
crease the specificity of individual nucleases. The first
approach relies on mutants of Cas9, known as nickases,
that cleave only one of the two DNA strands. Using such
mutants, a double strand break can be generated by target-
ing a pair of closely linked single-strand breaks (nicks) on
opposite DNA strands. The requirement that these nicks
coincide drastically improves targeting specificity com-
pared to that of single CRISPR nucleases [44,117,119,124].
A variant of this approach combines the CRISPR/Cas9
DNA binding activity with the FokI endonuclease, whose
dimerization requirements ensure that no nicking occurs
at off-target sites [109,125]. For efficient cleavage, these
‘paired nickase’ approaches require that adjacent target
sites, offset by up to 30 nucleotides, can be found on
opposite DNA strands.
A second approach to increase the specificity of targeting
by CRISPR relies on the observation that short recognition
sequences are less forgiving in terms of allowed mismatches
between the guide RNA and its targets [88] (similar obser-
vations on specificity and target size have been made with
TALENs, [65]). Thus, guide RNAs with targeting sequences
of 17 to 19 nucleotides show high targeting efficiencies and
much reduced off-target effects compared to ones with
canonical 20-nucleotide targeting sequences [88].
Ultimately, it may also be possible to improve the
stringency of CRISPR target recognition by selecting or
engineering Cas9 nucleases that are intrinsically less
promiscuous.
Opportunities for evo-devo and future challenges
CRISPR-mediated gene targeting opens a wide range of
opportunities, both in established model organisms and
in newly emerging ones. A quick guide for applying
CRISPR in new species is given in Table 2.
Table 2 A quick guide to CRISPR for beginnersa
1. Prerequisites
• Delivery method, reaching the germline or other cells of interest: microinjection, transfection, electroporation
• Genomic sequence of target genes
• Robust phenotypic assays to determine the effect of gene targeting
2. Experimental strategy
• Decide on the targeting approach (knock-in or knock-out), depending on whether you want to disrupt gene function, engineer a specific
mutation, generate a reporter, etcetera.
• When testing CRISPR for the first time, choose a simple knock-out approach, selecting targets that produce phenotypes that are easy to score,
such as pigmentation genes or a GFP transgene [70,98,122], or genes with a known, robust and specific phenotype.
For knock-ins
• To knock-in large constructs, use HDR templates in which the knock-in construct is flanked by homology arms - typically >1 kb in length - matching
the sequences on either side of the double-strand break [46-49]; shorter homology arms give lower efficiencies [50]. Provide the template as a circular
plasmid.
• To introduce small changes, use synthetic single-stranded oligos (ssODNs) bearing 10 to 40 nucleotides of homologous sequence at each end
as templates for HDR [48,50-52].
• The sequence targeted by CRISPR should be mutated in the repair template to protect the template and targeted alleles from cleavage.
• Alternatively, a homology-independent knock-in approach (see Figure 1) may be used to knock-in large DNA fragments [42,45] or short
double-stranded oligos (dsODNs) [44]. Using this approach, the insertion may be imprecise [45] or directed by complementary overhangs
[42,44].
• Select an approach that will minimize lethality due to NHEJ-mediated indels in somatic tissues, for example, by restricting CRISPR/Cas activity to
the germline [48,123], targeting constructs to introns, or adopting a strategy that improves the relative efficiency of knock-ins [42,45,50].
3. Design of guide RNAs - finding target sequences
• Use the most reliable genomic sequence available for the target gene. Consider that the targeted site may bear nucleotide polymorphisms; if
this is likely to be an issue, obtain sequences from the strain used for gene targeting and/or test multiple guide RNAs.
• Use online software to search for potential target sites (see Online Resources for CRISPR, below). The software search a given sequence for sites
with a suitable PAM motif (NGG for S. pyogenes Cas9) and additional sequence constraints depending on the mode of guide RNA production
(GGN18NGG for in vitro T7-synthesis of guide RNAs, GN19NGG for U6-mediated expression). The latter requirements can be relaxed, as extra Gs
may be added to the 5′ end of the guide RNA without significantly compromising targeting efficiency [51,88].
• When working with a sequenced genome, the software can also detect potential unintended targets and help select guide RNAs with
fewer off-targets.
• Although the presence of the PAM sequence at the genomic target site is essential, it should not be included in the guide RNA (see Figure 2).
For an N20NGG target site, only the N20 sequence is incorporated at the 5′end of the guide RNA.
• Design and test multiple guide RNAs, if possible, to control for off-target effects and because some guide RNAs fail (due to polymorphisms, RNA
secondary structure or for unexpected reasons).
• Strategies to reduce off-target effects may require special design of guide RNAs: paired nickase approaches require pairs of target sequences offset by
no more that 30 nucleotides on opposite DNA strands [44,109,117,119,124,125]; truncated guide RNAs bear targeting sequences that are shorter than
20 nucleotides [88].
4. Providing guide RNAs and Cas9
• Guide RNAs are easily generated by cloning pairs of synthetic oligos, corresponding to the two strands of the target sequence (determined
above), into vectors carrying the invariable portion of the guide RNA (available at www.addgene.org/CRISPR). Cloning is facilitated by a restriction
site on the vector - usually BbsI or BsaI, which does not constrain the cloned sequence - and compatible overhangs in the annealed oligos.
• The guide RNAs can be expressed either by in vitro transcription via the bacteriophage T3, T7 or SP6 promoters, or by in vivo expression via the
U6 promoter. For initial experiments in species where U6 promoters and terminators are untested, choose in vitro synthesis of the guide RNA.
Vectors and protocols can be found at www.addgene.org/CRISPR.
• Cas9 can be expressed from a helper plasmid carrying the coding sequence of Cas9 under the control of an appropriate promoter. Alternatively,
if a promoter is unavailable for the species of interest, Cas9 can be provided in the form of in vitro transcribed capped mRNA or as purified
recombinant protein [104,105]. For initial experiments performed by microinjection, the use of recombinant Cas9 protein overcomes uncertainties
with untested promoters and mRNA translation.
5. Rapid assays of CRISPR activity and genotyping
• The melting curve and surveyor or T7E1 endonuclease assays are invaluable for a rapid assessment of CRISPR activity in new species, for routine
testing of new guide RNAs prior to more laborious experiments, and for genotyping animals at specific target sites. These assays detect indels
and other point mutations generated by NHEJ. They rely on PCR and require only a small amount of starting material.
• Genomic DNA is extracted from embryos or tissues to be tested and PCR is performed using primers that flank the target site. Untreated
genomic DNA gives a PCR product with perfectly annealed strands (unless there are natural polymorphisms within the fragment), whereas
mutagenized genomic DNA also yields some heteroduplex DNA, consisting of strands that differ by small indels and point mutations. The
following assays are used to detect of these mismatches.
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Table 2 A quick guide to CRISPR for beginnersa (Continued)
- Surveyor/T7E1 endonuclease assays are based on cleavage of the heteroduplexes by a mismatch-specific endonuclease - either Surveyor or
T7 endonuclease 1 [126,127]. Cleavage products, indicating the presence of mispaired DNA, are detected by electrophoresis on an agarose gel.
This is a sensitive detection method, best performed on 400 to 800 bp amplicons with target sites positioned near the middle.
- The melting curve assay [128] relies on the fact that heteroduplex DNA has a lower melting temperature than the corresponding
homoduplex fragments. That temperature difference, which is in the order of 1 to 2°C for 100 to 200 bp fragments, can be detected by
performing melting curves in real-time PCR instruments with high temperature resolution.
• More specific PCR-based assays can be devised for knock-in approaches, employing pairs of primers that span the genomic locus and knock-in
fragment.
• The PCR products can be cloned and sequenced to examine the nature and spectrum of corresponding mutations.
6. Scoring phenotypes
• The effects of CRISPR targeting can be assessed in the animals where CRISPR was delivered (G0) or in their progeny. It is important to keep in
mind that G0s are mosaics where only some cells are likely to carry alleles targeted by CRISPR; in the best cases a significant proportion of the
animal shows bi-allelic targeting and a corresponding phenotype. The degree and distribution of targeted cell clones however are difficult to
determine, unless a cell-autonomous marker is used (for example, targeting of some pigment genes, knock-in of GFP).
• If the germline of G0s has been hit, targeted alleles will be recovered in the next generation (G1). In contrast to G0s, G1 individuals are non-mosaic
and may inherit one targeted allele (per locus) from the CRISPR-targeted parent. Animals may be genotyped by PCR (see above) and crossed
to produce homozygotes and to maintain mutant lines.
• Choosing reliable, specific phenotypic assays and appropriate controls is crucial. Phenotypes may be subtle or show incomplete penetrance.
7. Off-target effects and controls
• Unintended targets (off-targets) may be anywhere in the genome and are difficult to predict. Two strategies can help to overcome problems
with off-target effects: appropriate experimental design allowing us to detect and account for off-target effects and approaches that improve
the specificity of CRISPR.
• In most cases it is possible to control for off-targets by using different guide RNAs to achieve targeting; guide RNAs targeting different sequences are
very unlikely to share the same off-targets. Alleles generated using different guide RNAs may be brought together by crossing, in heteroallelic combina-
tions that are likely to complement off-target mutations.
• The specificity of CRISPR can be significantly improved by using paired nickases [44,109,117,119,124,125] or truncated guide RNAs [88] (see
main text).
• Off-target mutations will segregate away from targeted alleles in genetic crosses, unless they are linked on the chromosome.













• CRISPR technology is recent and rapidly evolving. Online resources are likely to change, as improvements and new tools are introduced.
aUseful practical advice and a protocol (applied to cell lines) can also be found in [129].
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applied in newly established experimental systems due
to the extraordinary efficiency of NHEJ-mediated knock-
out, which approaches 100% in some species. Generating
a null-allele or disrupting a specific cis-regulatory elem-
ent now seems within reach in a wide range of animals
and will be primarily limited by our ability to screen forthese mutations (by phenotype or by PCR) and to main-
tain mutant stocks.
To some extent, the high efficiency of CRISPR- and
TALEN-mediated knock-out may also help to overcome
the problem of stock-keeping. The high frequency of
bi-allelic knock-out in injected embryos using CRISPR
or TALEN has raised the possibility of carrying out ‘G0
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embryos (for example, [48,98,122,130,131]). Phenotypic
analysis without crosses could be used as a ‘quick and
dirty’ approach in species that have long generation
times, or for preliminary screens on a large number of
candidate genes, similar to RNAi. The obvious drawback
of this type of analysis is the genetic mosaicism of the
organism, which is difficult to control and will lead to
partial and variable phenotypes.
However, mosaicism could also be an advantage in
contexts where genetic manipulation within specific cell
lineages or in random cell clones is desirable to over-
come lethality, or to assess cell autonomous versus
non-autonomous effects of gene function. Particularly so
when the extent of mosaicism can be monitored or
manipulated (see [48]). Tissue- and stage-specific knock-
outs may be achieved by manipulating the expression of
Cas9 [48].
Knock-in approaches provide an even wider range of op-
portunities, including precise modification of genes in their
native genomic context, and generating visible reporters
for regulatory and physiological events, and drivers for
transgene expression. The major challenge to overcome
here is that, for any given guide RNA or TALEN, the
frequency of mutagenic NHEJ repair will be much higher
(by an order of magnitude) than the frequency of HDR- or
NHEJ-driven knock-in (see Figure 1). A high knock-out
frequency in the somatic cells of injected animals can lead
to lethality that prevents knock-ins to be recovered in the
next generation. This problem could be overcome in a
number of ways: by using germline-specific cis-regulatory
elements to restrict the activity of Cas9 to the germline
[48,123]; by targeting sites that are unlikely to be lethal if
mutated, for example, targeting knock-ins to intronic
sequences, with appropriate splice signals to generate
functional gene fusions; by finding ways to improve the
efficiency of HDR relative to NHEJ, such as by knocking
down the activity of DNA ligase 4 or other factors that are
essential for NHEJ [49,50,132]; or by developing strategies
that exploit NHEJ-mediated gene knock-ins to achieve
higher efficiencies [42-45] (see Figure 1).
Beyond knock-out and knock-in strategies, the ability
to direct double-strand breaks to specific sites in the
genome raises the prospect of chromosome engineering.
Generating chromosomal deletions and inversions is
presently not one of the usual tools employed in evo-devo,
but one only needs to consider the enormous contribution
of balancer chromosomes in Drosophila genetics to appre-
ciate its potential value in emerging model organisms
[133]. Balancers are invaluable tools for selecting and
keeping track of chromosomes bearing mutations, es-
pecially when these mutations are deleterious and not
associated with a dominant marker (for example, the
knock-out of an essential gene). CRISPR and TALENsnow allow us to generate targeted chromosomal inver-
sions [134-136] associated with recessive lethal mutations
and, thus, to create balancers, in organisms where a gen-
ome sequence and map are available.
Last but not least, the customizable specificity of
CRISPR may be harnessed to direct other molecular
effectors - besides nucleases - to specific sites in the
genome (reviewed in [137]). For example, catalytically
inactive versions of Cas9 have been used to interfere
with transcription [138,139], coupled with transcrip-
tional activators, repressors or chromatin modifiers to
generate artificial transcriptional regulators [117,139-143],
or linked with fluorescent proteins to reveal chromosome
dynamics [144]. This approach allows us to manipulate
the activity of regulatory elements in their native context
without introducing changes in their nucleotide sequence,
providing tools of unprecedented precision in our efforts
to manipulate and to understand gene regulation.
CRISPR technology is young - barely two years old -
and still rapidly evolving. Improvements, new applica-
tions and adaptations of the technique to new species
have been published at overwhelming speed during the
last year, and surely more are forthcoming. This is a true
revolution for comparative studies. Practical issues, such
as the delivery method and our ability to select and to
propagate mutants, are still likely to limit the full de-
ployment of CRISPR in many species. Notwithstanding
these issues, targeted mutagenesis and precise gene
editing are now within reach in a very wide range of
organisms.
Endnotes
aIt is interesting to note that the adaptive diversifica-
tion, specificity and efficiency of immunity mechanisms
provide the basis for some of the most powerful tools in
molecular biology: restriction enzymes, antibodies, RNAi
and CRISPR.
bSomewhat shorter sequences may also be used (see
Off-target effects).
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